These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 36522208

  • 21. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.
    Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, Chiang CY, Conradie F, Gopalan N, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Teferi M, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID, STREAM study collaborators.
    Lancet Respir Med; 2024 Dec; 12(12):975-987. PubMed ID: 39366400
    [Abstract] [Full Text] [Related]

  • 22. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
    Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL, Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin R, Papineni P, Nunn AJ, Crook AM, TRUNCATE-TB Trial Team.
    N Engl J Med; 2023 Mar 09; 388(10):873-887. PubMed ID: 36808186
    [Abstract] [Full Text] [Related]

  • 23. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.
    Lancet; 2018 Sep 08; 392(10150):821-834. PubMed ID: 30215381
    [Abstract] [Full Text] [Related]

  • 24. Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study.
    Morgan H, Ndjeka N, Hasan T, Gegia M, Mirzayev F, Nguyen LN, Schumacher S, Schlub TE, Naidoo K, Fox GJ.
    Clin Infect Dis; 2024 Jun 14; 78(6):1698-1706. PubMed ID: 38525535
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 26. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M, ZeNix Trial Team.
    N Engl J Med; 2022 Sep 01; 387(9):810-823. PubMed ID: 36053506
    [Abstract] [Full Text] [Related]

  • 27. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY, Lin CJ.
    Indian J Tuberc; 2020 Dec 01; 67(4S):S16-S22. PubMed ID: 33308663
    [Abstract] [Full Text] [Related]

  • 28. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D.
    Lancet Respir Med; 2018 Apr 01; 6(4):265-275. PubMed ID: 29595509
    [Abstract] [Full Text] [Related]

  • 29. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
    Stagg HR, Bothamley GH, Davidson JA, Kunst H, Lalor MK, Lipman MC, Loutet MG, Lozewicz S, Mohiyuddin T, Abbara A, Alexander E, Booth H, Creer DD, Harris RJ, Kon OM, Loebinger MR, McHugh TD, Milburn HJ, Palchaudhuri P, Phillips PPJ, Schmok E, Taylor L, Abubakar I, London INH-R TB study group.
    Eur Respir J; 2019 Oct 01; 54(4):. PubMed ID: 31371444
    [Abstract] [Full Text] [Related]

  • 30. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T, Lee SJ, Jeon D, Lee HY, Kim HJ, Kang BH, Mok J.
    J Korean Med Sci; 2021 Jul 05; 36(26):e174. PubMed ID: 34227261
    [Abstract] [Full Text] [Related]

  • 31. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH, Kang BH, Lee T, Lee HK, Jang HJ, Cho YJ, Jeon D.
    J Korean Med Sci; 2017 Apr 05; 32(4):636-641. PubMed ID: 28244290
    [Abstract] [Full Text] [Related]

  • 32. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
    Dawson R, Diacon AH, Takuva S, Liu Y, Zheng B, Karwe V, Hafkin J.
    Trials; 2024 Jan 19; 25(1):70. PubMed ID: 38243296
    [Abstract] [Full Text] [Related]

  • 33. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020.
    Avaliani T, Sereda Y, Davtyan H, Tukvadze N, Togonidze T, Kiria N, Denisiuk O, Gozalov O, Ahmedov S, Hovhannesyan A.
    Monaldi Arch Chest Dis; 2021 Jan 14; 91(1):. PubMed ID: 33470088
    [Abstract] [Full Text] [Related]

  • 34. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    De Castro N, Marcy O, Chazallon C, Messou E, Eholié S, N'takpe JB, Bhatt N, Khosa C, Timana Massango I, Laureillard D, Chau GD, Domergue A, Veloso V, Escada R, Wagner Cardoso S, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B, ANRS 12300 Reflate TB2 study group.
    Lancet Infect Dis; 2021 Jun 14; 21(6):813-822. PubMed ID: 33667406
    [Abstract] [Full Text] [Related]

  • 35. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W, Zheng M, Wang B, Mu X, Li P, Fu L, Liu S, Guo Z.
    Int J Infect Dis; 2016 Nov 14; 52():23-28. PubMed ID: 27613365
    [Abstract] [Full Text] [Related]

  • 36. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial.
    Ruslami R, Fregonese F, Apriani L, Barss L, Bedingfield N, Chiang V, Cook VJ, Fisher D, Flores E, Fox GJ, Johnston J, Lim RK, Long R, Paulsen C, Nguyen TA, Nhung NV, Gibson D, Valiquette C, Benedetti A, Menzies D.
    Lancet Respir Med; 2024 Jun 14; 12(6):433-443. PubMed ID: 38552659
    [Abstract] [Full Text] [Related]

  • 37. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
    Cross GB, Sari IP, Kityo C, Lu Q, Pokharkar Y, Moorakonda RB, Thi HN, Do Q, Dalay VB, Gutierrez E, Balanag VM, Castillo RJ, Mugerwa H, Fanusi F, Kwan P, Chew KL, Paton NI, ROSETTA trial team.
    Lancet Infect Dis; 2023 Jul 14; 23(7):847-855. PubMed ID: 36966799
    [Abstract] [Full Text] [Related]

  • 38. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y.
    Antimicrob Agents Chemother; 2012 Nov 14; 56(11):5465-75. PubMed ID: 22869570
    [Abstract] [Full Text] [Related]

  • 39. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial.
    Ubals M, Nadal-Baron P, Arando M, Rivero Á, Mendoza A, Descalzo Jorro V, Ouchi D, Pérez-Mañá C, Álvarez M, Alemany A, Hoyos-Mallecot Y, Nunley E, Lieberman NAP, Greninger AL, Galván-Casas C, Suñer C, G-Beiras C, Paredes R, Rodríguez-Gascón A, Canut A, García-Patos V, Farré M, Marks M, Giacani L, Vall-Mayans M, Mitjà O.
    Lancet Infect Dis; 2024 Apr 14; 24(4):404-416. PubMed ID: 38211601
    [Abstract] [Full Text] [Related]

  • 40. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
    Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K, TB-PRACTECAL Study Collaborators.
    N Engl J Med; 2022 Dec 22; 387(25):2331-2343. PubMed ID: 36546625
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.